Upon diagnosis of fibrosis by the FIB-4 score, the APRI, and the NAFLD score, chemerin declined in patients with more advanced liver fibrosis (Figure 3C–E). This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatotic liver disease.